Lapierre Marion, Castet-Nicolas Audrey, Gitenay Delphine, Jalaguier Stéphan, Teyssier Catherine, Bret Caroline, Cartron Guillaume, Moreaux Jérôme, Cavaillès Vincent
IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.
INSERM, U1194, Montpellier, F-34298, France.
J Hematol Oncol. 2015 Mar 4;8:20. doi: 10.1186/s13045-015-0116-6.
RIP140 is a transcriptional coregulator, (also known as NRIP1), which finely tunes the activity of various transcription factors and plays very important physiological roles. Noticeably, the RIP140 gene has been implicated in the control of energy expenditure, behavior, cognition, mammary gland development and intestinal homeostasis. RIP140 is also involved in the regulation of various oncogenic signaling pathways and participates in the development and progression of solid tumors. During the past years, several papers have reported evidences linking RIP140 to hematologic malignancies. Among them, two recent studies with correlative data suggested that gene expression signatures including RIP140 can predict survival in chronic lymphocytic leukemia (CLL). This review aims to summarize the literature dealing with the expression of RIP140 in CLL and to explore the potential impact of this factor on transcription pathways which play key roles in this pathology.
RIP140是一种转录共调节因子（也称为NRIP1），它精细调节各种转录因子的活性并发挥非常重要的生理作用。值得注意的是，RIP140基因与能量消耗、行为、认知、乳腺发育和肠道稳态的调控有关。RIP140还参与各种致癌信号通路的调节，并参与实体瘤的发生和发展。在过去几年中，几篇论文报道了将RIP140与血液系统恶性肿瘤联系起来的证据。其中，两项最近的相关性研究表明，包括RIP140在内的基因表达特征可以预测慢性淋巴细胞白血病（CLL）的生存率。本综述旨在总结有关RIP140在CLL中表达的文献，并探讨该因子对在这种病理中起关键作用的转录途径的潜在影响。
